Abstract library

7 results for "Tajima".
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3
Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Takuji Okusaka
Authors: Okusaka T, Ito T, Ikeda M, Tajima T, ...
#930 Distinct Expression of Splicing Variants of the Human MEN1 (Multiple Endocrine Neoplasia Type 1) Gene in Various Pituitary Adenomas
Introduction: MEN1 is an autosomal-dominant tumor syndrome characterized by the occurrence of tumors in multiple endocrine tissues, including parathyroid, enteropancreatic neuroendocrine and anterior pituitary. The MEN1 gene consists of 10 exons transcribed into a 610 a.a. protein. It was reported that heterogeneity of human MEN1 gene transcripts related to variation in their 5’ UTR. Six distinct exsons1 (e1A-e1F) were isolated using RNA from thymus, pancreas and kidney.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Atsushi Ozawa
Keywords: MEN1, pituitary
#1286 A Comparative Analysis of Ki67 Index of the High Grade Neuroendocrine Neoplasms Arising in the Gastrointestinal Tract and the Pancreas
Introduction: A common classification has been used for NET in gastrointestinal tract (GI-NET) and pancreas (P-NET), but heterogeneity has been reported in high grade tumors; well-differentiated G3 (WDG3), poorly differentiated NEC (NEC), and mixed adenoneuroendocrine carcinoma (MANEC).
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1668 Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3
Introduction: The classification of lung neuroendocrine neoplasms (Lung-NENs) according to the WHO classification 2010 for GEP-NENs, including a provisional category for Lung-NET G3 with Ki67 >20%, may have prognostic implications.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Authors: Kasajima A, Oka N, Ishida H, Sakurada A, ...
Keywords: Lung NEN
#2198 PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung
Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Atsuko Kasajima
Keywords: Lung NEN, PD-L1, Prognosis